Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Hegde, Upendra P.
Funding for this research was provided by:
National Institutes of Health (PHS grant PO1 CA132681)
unspecified valid from 2017-05-11